Pharmaceuticals, heavy trucks, and furniture targeted in a move that could spark fresh inflation fears and impact corporate profits.
Precious metal outpaces gold as shrinking stockpiles and soaring industrial demand fuel a powerful market rally.
The approval of the twice-daily pill remibrutinib positions the company to challenge injectable treatments in a multi-billion dollar market.
Late-breaking trial results for obefazimod show significant efficacy, positioning the first-in-class oral therapy in a competitive market.
The ongoing US government shutdown is delaying critical jobs and inflation reports, creating an information vacuum for investors and the Federal Reserve.
Proposed 'OBBBA' legislation would hike tax credits for new domestic chip plants to 35%, aiming to accelerate 'Made in America' initiatives.
Combination therapy approval for small cell lung cancer offers a new standard of care and a bullish signal for the pharmaceutical sector.
Landmark bill grants Uber and Lyft drivers collective bargaining rights, signaling a potential shift in the gig work model.